A well-meaning FDA policy is a threat to pediatric cancer treatment
- OPACC
- Dec 16, 2023
- 1 min read
The medical community today faces a deceptively simple question: How quickly should we act when a child’s life is on the line? I’m a pediatric oncologist, so my answer won’t surprise you — I think we should act immediately. But a new Food and Drug Administration policy could delay things for children who need treatment now.
Recent Posts
See AllThe FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade gliomas, a type...
Untreated growth hormone deficiency was associated with neurocognitive impairment and reduced physical functioning among adult survivors...
A Phase I clinical trial demonstrated that a targeted approach to treating a deadly brain tumor in children called diffuse intrinsic...
Comments